Ubs Group Ag Oragenics Inc Transaction History

Ubs Group Ag

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.23 - $14.18 $3,926 - $242,095	-17,073 Reduced 89.18%	2,072 $0
Q2 2022 Aug 10, 2022	SELL	$0.24 - $0.42 $2,858 - $5,001	-11,909 Reduced 38.35%	19,145 $7,000
Q1 2022 May 16, 2022	BUY	$0.33 - $0.56 $4,597 - $7,801	13,931 Added 81.36%	31,054 $11,000
Q4 2021 Feb 14, 2022	BUY	$0.43 - $0.69 $4,540 - $7,286	10,560 Added 160.9%	17,123 $8,000
Q3 2021 Nov 15, 2021	BUY	$0.58 - $0.84 $1,197 - $1,733	2,064 Added 45.88%	6,563 $4,000
Q2 2021 Aug 13, 2021	BUY	$0.6 - $0.89 $2,699 - $4,004	4,499 New	4,499 $3,000
Q1 2021 May 12, 2021	SELL	$0.52 - $1.52 $6,036 - $17,644	-11,608 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$0.39 - $0.6 $1,015 - $1,562	-2,604 Reduced 18.32%	11,608 $5,000
Q3 2020 Nov 12, 2020	BUY	$0.56 - $1.49 $2,755 - $7,330	4,920 Added 52.95%	14,212 $8,000
Q2 2020 Jul 31, 2020	BUY	$0.39 - $0.83 $3,518 - $7,489	9,023 Added 3354.28%	9,292 $6,000
Q1 2020 May 01, 2020	SELL	$0.43 - $0.75 $28,197 - $49,182	-65,576 Reduced 99.59%	269 $0
Q4 2019 Feb 14, 2020	BUY	$0.42 - $0.62 $11,721 - $17,302	27,908 Added 73.56%	65,845 $34,000
Q3 2019 Nov 14, 2019	BUY	$0.36 - $0.64 $13,657 - $24,279	37,937 New	37,937 $20,000
Q1 2019 May 14, 2019	SELL	$0.57 - $1.05 $864 - $1,591	-1,516 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$0.78 - $3.57 $1,182 - $5,412	1,516 New	1,516 $1,000
Q3 2018 Nov 14, 2018	SELL	$0.38 - $1.42 $1,943 - $7,261	-5,114 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$1.16 - $2.0 $3,163 - $5,454	2,727 Added 114.24%	5,114 $7,000
Q1 2018 May 15, 2018	BUY	$1.6 - $3.17 $3,819 - $7,566	2,387 New	2,387 $4,000

Ticker OGEN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 116,395,000
Market Cap $36.1M
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immuni...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.